NOVAFED
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVAFED is an oral extended-release capsule small-molecule product approved in 1975 by Sanofi. The mechanism of action and specific indications are not publicly detailed in available data. This is a mature, legacy product approaching loss of exclusivity.
LOE Approaching
As a mature product approaching exclusivity loss with moderate competitive pressure (30%), the brand team is likely focused on defensive positioning and cost-management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NOVAFED currently has zero linked job openings, reflecting its mature lifecycle stage and approaching LOE. Assignment to this product may offer experience in defensive commercial strategy, generic transition planning, and cost-containment but limited opportunity for expansion or promotion.
Brand ManagerField Sales Representative
Worked on NOVAFED at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.